Menveo 1 vial was administered to a patient over 55years of age; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 67-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number 7gf79, expiry date 31-DEC-2025) for prophylaxis. On 15-NOV-2024, the patient received Menveo. On 15-NOV-2024, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: Menveo 1 vial was administered to a patient over 55years of age). The outcome of the inappropriate age at vaccine administration was unknown. Additional Information: GSK Receipt Date: 10-JAN-2025 The pharmacist called reporting Menveo 1 vial was administered to a patient over 55 years of age. The patient received it because she was going to be starting on a complement inhibitor. The pharmacist did not know if patient started treatment with this medication as she was waiting on the vaccines.